Sepsis, Severe

Infectious Diseases
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Artcline
ArtclineGermany - Rostock
1 program
1
ARTICEPhase 21 trial
Active Trials
NCT05442710Recruiting142Est. Jun 2026
Grifols
GrifolsNEW YORK, NY
1 program
20% AlbuminN/A1 trial
Active Trials
NCT05357339CompletedEst. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ArtclineARTICE
Grifols20% Albumin

Clinical Trials (2)

Total enrollment: 142 patients across 2 trials

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Start: Jul 2022Est. completion: Jun 2026142 patients
Phase 2Recruiting

Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock

Start: Sep 2021Est. completion: Dec 2023
N/ACompleted

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 142 patients
2 companies competing in this space